Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas

Journal of Clinical Oncology

Volumn 19, Issue 19, 2001, Pages 3918-3928

  Kaminski, M S ^a   Zelenetz, A D ^a   Press, O W ^a   Saleh, M ^a   Leonard, J ^a   Fehrenbacher, L ^a   Lister, T A ^a   Stagg, R J ^a   Tidmarsh, G F ^a   Kroll, S ^a   Wahl, R L ^a   Knox, S J ^a   Vose, J M ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; TOSITUMOMAB I 131;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MYELODYSPLASIA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035478728     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.19.3918     Document Type: Article

References (31)

1. The natural history of initially untreated low-grade non-Hodgkin's lymphoma
2. The treatment of indolent lymphomas: Watchful waiting vs. aggressive combined modality treatment
3. Follicular lymphoma: Prognostic factors for response and survival
4. Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center
5. Histologic conversion in the non-Hodgkin's lymphomas
6. Histological transformation of non-Hodgkin's lymphoma: A prospective study
7. Histologic progression in non-Hodgkin's lymphoma
8. Follicular low-grade non-Hodgkin's lymphoma: Long-term outcome with or without tumor progression
9. Incidence, predictive factors and outcome of lymphoma transformation in follicular lymphoma patients
10. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
11. Conventional treatments for non-Hodgkin's lymphoma: The need for new therapies
12. Radioimmunotherapy of B-cell lymphoma with 131I anti-B 1 (anti-CD20) antibody
13. Iodine I 131 tositumomab radioimmunotherapy for B-cell lymphoma
14. Radioimmunotherapy with Iodine I 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
15. Multicenter Phase II Study of Iodine I 131 tositumomab for chemotherapy-relapsed/refractory low-grade B-cell non-hodgkin's lymphomas
16. Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent 1,3,4,6-tetrachloro-3a-6a-diphenylglycouril (iodogen)
17. Centralized radiolabeling of antibodies for radioimmunotherapy
18. Patient-specific whole body dosimetry: Principles and a simplified method for clinical implementation
19. Nonparametric estimation from incomplete observations
20. Note on the sampling error of the difference between correlated proportions or percentages
21. 2 test
22. Evaluation of survival data and two new rank order statistics arising in first consideration
23. Regression models and life tables
24. A predictive model for aggressive NHL: The international non-Hodgkin's lymphoma prognostic factors project
25. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
26. Therapy-related leukemias: Susceptibility, prevention and treatment
27. Nonmyeloablative iodine-131 radioimmunotherapy as outpatient therapy
28. Radiation doses received by non-occupational caregivers exposed to NHL patients receiving radioimmunotherapy